EU/3/14/1236: Orphan designation for the treatment of epidermolysis bullosa



On 19 February 2014, orphan designation (EU/3/14/1236) was granted by the European Commission to Prof. Johann W. Bauer, Austria, for diacerein for the treatment of epidermolysis bullosa.

The sponsorship was transferred to Medpace Finland OY, Finland, in November 2016.

The sponsorship was transferred to Diaderm GmbH, Austria in September 2021.

Key facts

Active substance
Intented use
Treatment of epidermolysis bullosa
Orphan designation status
EU designation number
Date of designation

Diaderm GmbH
Dr.-Franz-Rehrl-Platz 2
5020 Salzburg
tel: +43 (0) 5 7255-82405

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating